InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,535.60
(
0.66%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.70
(
0.00%
)
Bitcoin
66,162.50
(
1.84%
)
Post# of 320
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

milehighbuck

Send PM Follow Ignore
Followers 10
Posts 2020
Boards Moderated 0
Alias Born 04/11/2009

milehighbuck

Re: rickochey post# 176

Sunday, 04/11/2010 2:14:31 PM

Sunday, April 11, 2010 2:14:31 PM

Post# of 320
BLA approval is very likely, given the facts that it is approved on a "named patient" basis in Europe and the FDA granted "Orphan Drug status". However, you never know for sure until it is a done deal.

Check out Dendreon DNDN. They are in the same vaccine space but for prostate cancer. IIRC, about a year ago they were at 2.50 and now they trade around $35.00.

The first step is emerging from bankruptcy. That should happen by June and it may be eminent. As soon as they are out of bankruptcy re-org the stock will really move.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up